Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.71 |
| ▸ | LMNA | P02545 | 2/20 | 0.65 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | PDE4A | P27815 | 1/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.41 |
| ▸ | MGAM | O43451 | 5/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | TOP1 | P11387 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3761094 | 1.00 | TDP1 (0.71) | TDP1LMNAL3MBTL1KDM4EPDE4A | |
| SCHEMBL11753239 | 1.00 | TDP1 (0.71) | TDP1LMNAL3MBTL1KDM4EPDE4A | |
| SCHEMBL3050298 | 0.97 | LMNA (0.69) | TDP1LMNAL3MBTL1KDM4EPDE4A | |
| SCHEMBL8348104 | 0.97 | LMNA (0.69) | TDP1LMNAL3MBTL1KDM4EPDE4A | |
| SCHEMBL1302931 | 0.97 | LMNA (0.69) | TDP1LMNAL3MBTL1KDM4EPDE4A | |
| SCHEMBL17101325 | 0.97 | LMNA (0.69) | TDP1LMNAL3MBTL1KDM4EPDE4A | |
| SCHEMBL219171 | 0.97 | LMNA (0.69) | TDP1LMNAL3MBTL1KDM4EPDE4A | |
| SCHEMBL865783 | 0.88 | — | — | |
| SCHEMBL148513 | 0.88 | — | — | |
| SCHEMBL17101240 | 0.88 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180344648-A1 | CLOBAZAM TABLET FORMULATION AND PROCESS FOR ITS PREPARATION | Piramal Enterprises Limited (IN) | 2018-12-06 | — | — | US | claimed |
| WO-2006014409-A1 | METHOD OF TREATING ANIMAL’S EXTERIOR FOR CLEANING AND/OR INSECT REPELLENCY | ACHTMANN HANS (US) | 2006-02-09 | — | — | WO | disclosed |
| EP-0231714-A1 | Nematicide and insecticide compositions containing heterocyclic compounds | RHONE-POULENC AGROCHIMIE (FR) | 1987-08-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180344648-A1 | CLOBAZAM TABLET FORMULATION AND PROCESS FOR ITS PREPARATION | SI, SLC6A13, SLC6A11 | TDP1 3667/4885LMNA 3037/4885L3MBTL1 4304/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.